Filtered By:
Drug: Rituxan
This page shows you your search results in order of relevance. This is page number 3.
Order by Relevance | Date
Total 7090 results found since Jan 2013.
Where to start? Upfront therapy for follicular lymphoma in 2018.
Authors: Leonard JP, Nastoupil LJ, Flowers CR
Abstract
The initial approach to the management of follicular lymphoma (FL) is challenging for patients and physicians. Most FL patients present with minimal symptoms; given the lack of a survival benefit to early treatment in this population, a period of observation without therapy is often appropriate. Once there is disease progression beyond low-tumor-burden criteria or symptoms prompting intervention, patients may be considered for an array of potential treatment options. These range from single-agent rituximab (anti-CD20) to various forms of chemoimmunotherapy, inc...
Source: Hematology ASH Education Program - December 7, 2018 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
Rapid Rituximab: An Inpatient Pilot Project to Increase Education and Use Among Oncology Nurses
Clin J Oncol Nurs. 2022 Jul 25;26(4):433-437. doi: 10.1188/22.CJON.433-437.ABSTRACT .PMID:35939733 | DOI:10.1188/22.CJON.433-437
Source: Clinical Journal of Oncology Nursing - August 8, 2022 Category: Nursing Authors: Casey Schade Source Type: research
